Tag: Sandoz

First FDA-Cleared PDT for Opioid Use Disorder

Sandoz Inc., a division of Novartis, and Pear Therapeutics, Inc., the leader in prescription digital therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has granted clearanc...

Novartis and Gan & Lee to Produce Insulin Biosimilars

Swiss drugmaker Novartis aims to become a big player in supplying insulin to swelling numbers of diabetics, signing a deal with China’s Gan & Lee on versions of three blockbuster brands as the U.S...

Sandoz and Pear Therapeutics launched the first digital therapeutic

digital drug
Sandoz, a Novartis division, and Pear Therapeutics, announced the commercial launch of reSET, the first FDA-authorized prescription digital therapeutic, for patients with Substance Use Disorder.

Novartis sells parts of its Sandoz US portfolio to Aurobindo Pharma

novartis
Novartis announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, to Aurobindo Pharma.

Sandoz obtained EC approval for infliximab biosimilar

Sandoz
Sandoz, a Novartis division and the global leader in biosimilars, announced that the European Commission (EC) has approved Zessly (infliximab) for use in Europe.

Sandoz and Pear Therapeutics will jointly develop digital therapeutics

digital drug
Sandoz, a Novartis division and global leader in generic pharmaceuticals and biosimilars, entered into a collaboration with Pear Therapeutics to commercialize and continued development of novel prescription digital therapeutics.

Tilray set up a strategic alliance with a leading Canadian pharma company

medicinal cannabis
Tilray, a licensed producer of medical cannabis, signed a binding letter of intent to be the collaborator of a major pharma company to accelerate innovation and increase availability of high quality medical cannabis products.

Sandoz and Biocon partnered to develop multiple biosimilars

biosimilars
Sandoz, a Novartis division, announced a global partnership with Asia's premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars

Sandoz obtained EU approval for Rixathon

Sandoz
Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced today that the European Commission (EC) has approved Rixathon